IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?

0472725 - MBÚ 2017 RIV US eng J - Článek v odborném periodiku
Tomala, Jakub - Kovář, Marek
IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?
Oncoimmunology. Roč. 5, č. 3 (2016), e1102829. ISSN 2162-402X. E-ISSN 2162-402X
Grant CEP: GA ČR GA13-12885S; GA MŠMT(CZ) ED1.1.00/02.0109
Institucionální podpora: RVO:61388971
Klíčová slova: Anti-IL-2 mAb * cancer immunotherapy * IL-2
Kód oboru RIV: EE - Mikrobiologie, virologie
Impakt faktor: 7.719, rok: 2016

he in vivo biological activity of IL-2 can be dramatically increased by complexing with anti-IL-2 mAb. Moreover, IL-2/anti-IL-2 mAb immunocomplexes selectively stimulate different subsets of immune cells, depending on the clone of anti-IL-2 mAb that is used. Thus, IL-2/S4B6 mAb complexes strongly stimulate CD122(high) populations, namely NK and memory CD8(+) T cells. They also intermediately stimulate T-reg cells. Conversely, IL-2/JES6.1 mAb immunocomplexes have no stimulatory activity for CD122(high) populations. However, they potently and highly selectively stimulate CD25(+) cells (i.e., T-reg and activated T cells). IL-2/S4B6 mAb immunocomplexes have also been shown to possess antitumor activity in various mouse tumor models.
Trvalý link: http://hdl.handle.net/11104/0269955